查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836974

RNA干擾技術市場（按分子類型、給藥途徑、遞送方式、應用和最終用戶）—全球預測 2025-2032

RNA Interference Technology Market by Molecule Type, Route Of Administration, Delivery Method, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年， RNA干擾技術市場將成長至 70.5 億美元，複合年成長率為 13.08%。

主要市場統計數據
基準年2024年 26.3億美元
預計2025年 29.5億美元
預測年份：2032年 70.5億美元
複合年成長率（%） 13.08%

為RNA干擾創新和商業化設定策略背景，包括治療開發、交付挑戰和監管勢頭

RNA干擾(RNAi) 已從實驗室現象發展成為一種經過臨床驗證的方法，對治療開發和生物醫學研究具有深遠的影響。過去十年，化學、遞送系統和監管清晰度的進步已將早期概念驗證轉化為認證核可藥，並催生了涵蓋多種適應症的候選藥物管線。因此，決策者必須將 RNAi 置於更廣泛的創新格局中，包括互補的基因編輯和寡核苷酸方法，同時認知到其獨特的技術限制和機會之窗。

這篇高階主管級別的介紹組裝RNAi既視為科學平台，也將其視為商業性提案。它強調了穩定性、標靶性和生產製造的改進如何減少了歷史障礙，而從偶聯物到奈米顆粒再到病毒載體，遞送技術的不斷發展也為臨床應用創造了差異化的途徑。最後，本節強調了在專案設計早期整合監管策略、付款人考量和下游生產準備的重要性，以降低開發風險並縮短對患者產生實際影響的時間。

技術和監管的快速轉變正在重新定義RNA干擾療法，從遞送平台到臨床檢驗和跨模式整合

在技​​術創新、監管先例和生態系統融合的推動下， RNA干擾領域正在經歷變革性變革。結合化學和標靶遞送機制的突破顯著提高了治療指標和組織特異性，使以往無法觸及的適應症成為可能。同時，日趨成熟的平台技術正在推動模組化開發方法的發展，使單一元素（例如遞送載體）的最佳化能夠在多個專案中重複使用。

監管機構也正在從概念指導轉向更具體的審查路徑，以減少不確定性，並實現更清晰的研發里程碑。同時，與基因編輯和mRNA療法等互補技術的跨模式整合，正在創造將持久敲低與編輯或瞬時表達相結合的混合策略，從而擴大可治療疾病的範圍。市場動態反映出平台開發商、契約製造和臨床合作夥伴之間日益密切的合作，這加速了轉化，同時也需要更複雜的聯盟管理和智慧財產權策略。總而言之，這些轉變正在將投資和管理重點轉向可擴展的交付、監管協調和策略夥伴關係。

2025 年美國關稅政策對全球 RNAi 供應鏈、採購和研究營運的預期累積影響

美國將於2025年實施累積關稅，凸顯了全球生命科學供應鏈的戰略脆弱性，給RNAi開發商和供應商帶來了新的成本和營運壓力。關稅導致進口試劑、特殊脂質和某些儀器組件的到岸成本上漲，引發了對籌資策略和多方採購計畫的重新評估。這促使企業加快對替代供應商的資格審查，優先考慮國內製造合作夥伴，並重新評估庫存管理實踐，以確保專案進度。

因此，企業正在重新調整其外包模式，以降低關稅波動帶來的風險，更加重視區域契約製造能力，並重新考慮關鍵原料的總擁有成本。同時，採購和法律團隊正在與研發部門更緊密地合作，以便在開發早期識別關稅敏感成分，從而減輕配方和製造選擇的影響。從戰略角度來看，關稅凸顯了供應鏈透明度、關鍵成分生產競爭前聯盟以及應急計劃的價值，以便在應對增量成本壓力的同時保持臨床發展勢頭。

按分子類別、遞送方法、給藥途徑、應用重點和最終用戶角色細分 RNAi 生態系統，以揭示策略重點

對RNAi生態系進行有意義的細分，可以明確科學研究成果與商業性機會的契合點。基於分子類型的市場研究涵蓋了微型RNA(miRNA)、短髮夾RNA (shRNA) 和小干擾RNA (siRNA)，其中短髮夾RNA進一步分析為非病毒遞送和病毒遞送的shRNA，而小干擾RNA則進一步分析為結合型和非結合型siRNA。這種分子分層揭示了不同的技術和調控途徑。 miRNA方法通常以通路調控為目標，shRNA構建體通常能夠實現持久的敲低，而載體選擇決定了其持久性，而siRNA程序則傾向於強調化學穩定性和靶標結合以實現精準遞送。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • GalNAc 偶聯 siRNA 療法在肝病標靶治療的應用日益廣泛
  • 擴展脂質奈米顆粒遞送平台以改善RNAi藥物的系統分佈
  • 基於RNAi的聯合治療的出現，旨在克服腫瘤治療中的抗藥性機制
  • AI驅動序列最佳化的進展提高了siRNA的效力並最大限度地減少了脫靶效應
  • 新型RNAi療法獲監管部門核准，推動罕見遺傳疾病應用投資
  • 生物製藥公司與學術界建立策略夥伴關係，共同創新RNAi遞送技術
  • 整合 CRISPR篩檢和 RNAi 文庫，加速神經退化性疾病研究中的標靶檢驗
  • 開發永續的大規模生產RNA干擾構建體的製造過程
  • 探索用於治療和治療局部肺部疾病的可吸入RNAi製劑
  • 人們對心血管疾病組織特異性RNAi療法的精準遞送平台的興趣日益濃厚

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章RNA干擾技術市場（依分子類型）

  • 微型RNA（miRNA）
  • 短髮夾RNA（shRNA）
    • shRNA的非病毒遞送
    • 病毒遞送的shRNA
  • 小干擾RNA（siRNA）
    • 結合siRNA
    • 未結合的siRNA

第9章RNA干擾技術市場（依管理途徑）

  • 肌肉注射
  • 鞘內（IT）給藥
  • 靜脈注射

第 10 章RNA干擾技術市場（以交付方式）

  • 直接裸RNAi遞送
  • 以外泌體為基礎的RNAi療法
  • 基於奈米粒子的遞送
  • 基於病毒載體的遞送

第11章RNA干擾技術市場（依應用）

  • 藥物研發
    • 先導藥物最適化
    • 目標識別
  • 研究與開發
    • 基因功能研究
    • 通路分析
  • 治療藥物

第12章RNA干擾技術市場（依最終用戶）

  • 合約研究組織
  • 醫院和診所
  • 製藥和生物技術公司

第13章RNA干擾技術市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章RNA干擾技術市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章RNA干擾技術市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Alnylam Pharmaceuticals, Inc.
    • AMSBIO
    • Arbutus Biopharma Corporation
    • Arcturus Therapeutics Holdings Inc.
    • Arrowhead Pharmaceuticals, Inc.
    • Atalanta Therapeutics
    • Bioneer Corporation
    • Dicerna Pharmaceuticals, Inc.
    • Gradalis, Inc.
    • Horizon Therapeutics plc
    • Ionis Pharmaceuticals, Inc.
    • Merck KGaA
    • Novartis AG
    • Nutcracker Therapeutics, Inc.
    • Phio Pharmaceuticals Corp.
    • ProQR Therapeutics NV
    • Sanofi SA
    • Silence Therapeutics PLC
    • Sirnaomics, Inc.
    • Thermo Fisher Scientific Inc.
    • Vir Biotechnology, Inc.
Product Code: MRR-0375F3EAA810

The RNA Interference Technology Market is projected to grow by USD 7.05 billion at a CAGR of 13.08% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.63 billion
Estimated Year [2025] USD 2.95 billion
Forecast Year [2032] USD 7.05 billion
CAGR (%) 13.08%

Setting the strategic context for RNA interference innovation and commercialization across therapeutic development, delivery challenges, and regulatory momentum

RNA interference (RNAi) has matured from a laboratory phenomenon into a clinically validated modality with durable implications for therapeutic development and biomedical research. Over the past decade, advances in chemistry, delivery systems, and regulatory clarity have converted early proofs of concept into approved drugs and a growing pipeline of candidates across multiple indications. As a result, decision-makers must situate RNAi within a broader innovation landscape that includes complementary gene editing and oligonucleotide approaches while recognizing unique technical constraints and opportunity windows.

This executive-level introduction frames RNAi as both a scientific platform and a commercial proposition. It highlights how improvements in stability, targeting, and manufacturing have reduced historical barriers while the ongoing evolution of delivery technologies-ranging from conjugates to nanoparticles to viral vectors-creates differentiated pathways for clinical translation. Finally, this section underscores the importance of integrating regulatory strategy, payer considerations, and downstream manufacturing readiness early in program design in order to de-risk development and accelerate time to meaningful patient impact.

Rapid technological and regulatory shifts redefining RNA interference therapeutics from delivery platforms to clinical validation and cross-modal integration

The landscape for RNA interference is undergoing transformative shifts driven by technical innovation, regulatory precedent, and ecosystem convergence. Breakthroughs in conjugation chemistry and targeted delivery mechanisms have materially improved therapeutic index and tissue specificity, enabling indications that were previously out of reach. Concurrently, the maturation of platform know-how is facilitating modular development approaches where optimization of one element-such as a delivery vehicle-can be reused across multiple programs, thereby increasing R&D efficiency and lowering program risk.

Regulatory agencies have also moved from conceptual guidance to more concrete review pathways, reducing uncertainty and enabling clearer development milestones. At the same time, cross-modal integration with complementary technologies such as gene editing and mRNA therapeutics is creating hybrid strategies that combine durable knockdown with editing or transient expression, expanding the scope of treatable diseases. Market dynamics reflect increased collaboration between platform developers, contract manufacturers, and clinical partners, which accelerates translation but also requires more sophisticated alliance management and IP strategies. Taken together, these shifts are reorienting investment and operational priorities toward scalable delivery, regulatory alignment, and strategic partnerships.

Anticipating the cumulative impact of United States tariff policies enacted in 2025 on global RNAi supply chains, sourcing, and research operations

The introduction of cumulative tariff measures by the United States in 2025 has emphasized the strategic fragility of global life sciences supply chains and highlighted new cost and operational pressures for RNAi developers and suppliers. Tariff-related increases in the landed cost of imported reagents, specialized lipids, and certain device components have triggered a reassessment of sourcing strategies and multi-sourcing plans. This has encouraged organizations to accelerate qualification of alternative suppliers, prioritize domestic manufacturing partnerships, and re-evaluate inventory management practices to preserve program timelines.

Consequently, companies are recalibrating their outsourcing models to reduce exposure to tariff volatility, increasing interest in regional contract manufacturing capacity, and reexamining the total cost of ownership for critical raw materials. In parallel, procurement and legal teams are working more closely with R&D to identify tariff-sensitive inputs early in development so that formulation design and process choices can mitigate exposure. From a strategic perspective, the tariffs have underscored the value of supply chain transparency, pre-competitive consortia for critical component production, and contingency planning that preserves clinical momentum while managing incremental cost pressures.

Segmenting the RNAi ecosystem by molecule class, delivery approach, administration route, application focus, and end-user roles to reveal strategic priorities

Meaningful segmentation of the RNAi ecosystem clarifies where scientific effort and commercial opportunity align. Based on Molecule Type, market studies consider MicroRNA (miRNA), Short Hairpin RNA (shRNA), and Small Interfering RNA (siRNA), with Short Hairpin RNA further examined across Non-Viral Delivery shRNA and Viral Delivery shRNA and Small Interfering RNA further analyzed as Conjugated siRNA and Non-Conjugated siRNA. This molecular stratification reveals distinct technical and regulatory pathways: miRNA approaches frequently target pathway modulation, shRNA constructs often enable durable knockdown with vector choices dictating persistence, and siRNA programs tend to emphasize chemical stabilization and targeted conjugation for precision delivery.

Based on Route Of Administration, the ecosystem is studied across Intramuscular (IM) Injection, Intrathecal (IT) Administration, and Intravenous (IV) Injection, each of which imposes different formulation, safety monitoring, and clinical trial design requirements. Based on Delivery Method, the field is appraised across Direct Naked RNAi Delivery, Exosome-Based RNAi Therapy, Nanoparticle-Based Delivery, and Viral Vector-Based Delivery, highlighting how payload, target tissue, and immunogenicity considerations drive modality selection. Based on Application, the landscape spans Drug Discovery, Research & Development, and Therapeutics, with Drug Discovery further broken down into Lead Optimization and Target Identification and Research & Development further divided into Gene Function Studies and Pathway Analysis. Finally, based on End-User, stakeholders include Contract Research Organizations, Hospitals & Clinics, and Pharmaceutical & Biotechnology Companies, each engaging with RNAi capabilities at different points in the value chain. Synthesizing these segmentation dimensions enables program teams to prioritize technical investments, align clinical strategy with administration routes, and select partners whose capabilities match the intended product profile.

Regional dynamics shaping RNAi development and commercialization across the Americas, Europe Middle East & Africa, and Asia-Pacific with distinct operational implications

Regional dynamics significantly influence how RNAi programs progress from discovery into clinical application. In the Americas, a combination of strong biotechnology venture investment, advanced clinical trial infrastructure, and regulatory familiarity has supported rapid translation of platform innovations into human studies. This geography also hosts a dense concentration of contract developers and specialized suppliers, making it an attractive location for late-stage process scale-up and commercial manufacturing partnerships.

In Europe, Middle East & Africa, regulatory harmonization across major markets and robust academic hubs drive translational science, while national centers of excellence contribute specialized capabilities in formulation and vector engineering. Market access pathways and payer negotiation dynamics in Europe require earlier demonstration of real-world outcomes and companion diagnostics in certain therapeutic areas. The Asia-Pacific region combines large patient populations for clinical enrollment, rapidly expanding biomanufacturing capacity, and active government initiatives to support biotechnology infrastructure. Taken together, these regional distinctions shape strategic choices about where to site clinical trials, manufacture drug product, and cultivate long-term partnerships based on regulatory environment, cost base, and talent availability.

Competitive and collaborative company behaviors shaping RNAi innovation through strategic partnerships, CDMO engagement, and intellectual property strategies

Company behavior in the RNAi domain is characterized by a mix of platform specialization, strategic partnerships, and increasing engagement with contract development and manufacturing organizations. Technology-focused firms concentrate on chemistry and delivery innovations that can be licensed across multiple programs, while diversified biopharma firms pursue in-house development for high-priority indications and selectively partner where complementary expertise accelerates timelines. At the same time, contract manufacturers and service providers are expanding capabilities to address formulation complexity and regulatory expectations for oligonucleotide therapies, creating a more modular ecosystem.

Competitive differentiation increasingly rests on the depth of delivery know-how, the strength and clarity of intellectual property portfolios, and the ability to execute late-stage manufacturing reliably. Partnerships and licensing deals remain common mechanisms to combine discovery-stage innovation with commercial-scale capabilities. Additionally, vertical integration is emerging as a strategic option for organizations seeking to control critical supply chain nodes, although this approach requires significant capital and operational sophistication. For emerging companies, judicious collaboration with experienced clinical development and manufacturing partners reduces execution risk and accelerates the path from concept to clinic.

Strategic actions for industry leaders to accelerate RNAi program success through delivery investment, regulatory alignment, and supply chain resilience

Industry leaders should adopt a set of actionable priorities to translate RNAi potential into durable clinical and commercial outcomes. First, invest in delivery platform capabilities that match target tissues and clinical objectives, recognizing that delivery choices made during early development materially affect safety, efficacy, and scalability. Second, develop supply chain resilience plans that include qualified alternate suppliers, regional manufacturing options, and inventory strategies to mitigate tariff and geopolitical disruption. Third, pursue regulatory engagement early and often, using pre-submission meetings and adaptive trial designs to align safety monitoring and endpoint selection with payer expectations.

Moreover, leaders should pursue strategic partnerships with contract development and manufacturing organizations to de-risk scale-up while retaining optionality for manufacturing ownership in the future. They should also prioritize data interoperability and real-world evidence collection to support both regulatory submissions and payer value demonstration. Finally, invest in talent and governance structures that enable rapid learning across platforms-creating cross-functional teams that bridge discovery chemistry, translational pharmacology, clinical development, and commercial strategy to accelerate decision-making and program progress.

Transparent and rigorous research methodology combining expert engagement, secondary synthesis, and triangulation to validate RNAi strategic insights

This research employs a rigorous mixed-methods approach combining primary qualitative engagement with subject-matter experts and structured secondary synthesis of public scientific and regulatory sources. Primary research included interviews with clinicians, formulation scientists, regulatory advisors, and manufacturing specialists to capture practical constraints and near-term operational considerations. These conversations informed hypothesis generation around delivery trade-offs, route-specific safety considerations, and regional implementation barriers.

Secondary research synthesized peer-reviewed literature, clinical trial registries, regulatory guidance documents, and company disclosures to contextualize primary insights and validate technical assertions. Data triangulation ensured that conclusions reflected convergent evidence rather than single-source assumptions, and quality checks included cross-validation of technical details with independently published protocols and regulatory filings. The methodology also accounted for limitations, noting areas where data remain emergent-such as long-term real-world safety for new delivery modalities-and recommending targeted follow-up studies to address these gaps.

Concluding perspectives on the strategic imperatives for RNAi development as science, delivery, and policy converge to shape clinical impact

In summary, RNA interference stands at a strategic inflection point where sustained scientific progress, evolving regulatory clarity, and commercial interest converge to expand therapeutic potential. Progress in delivery chemistry and platform optimization is unlocking indications that require precise tissue targeting, while regulatory precedents reduce some historical uncertainty for program development. Nevertheless, operational and strategic complexity has increased: supply chain dynamics, geopolitical considerations, and the imperative to demonstrate real-world value demand integrated planning across discovery, development, and commercialization functions.

Organizations that succeed will be those that harmonize scientific ambition with pragmatic operational execution-investing early in delivery solutions, diversifying sourcing and manufacturing strategies, engaging regulators proactively, and forming targeted partnerships to access missing capabilities. By aligning technical design choices with clinical and commercial constraints, program teams can accelerate translation while preserving flexibility to adapt to emerging data and market signals. The path forward requires disciplined program design, robust external collaboration, and sustained investment in the capabilities that convert molecular promise into patient benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of GalNAc-conjugated siRNA therapeutics for targeted liver disease treatment
  • 5.2. Expansion of lipid nanoparticle delivery platforms to improve systemic distribution of RNAi drugs
  • 5.3. Emergence of RNAi-based combination therapies to overcome resistance mechanisms in oncology treatments
  • 5.4. Advances in AI-driven sequence optimization for enhanced siRNA potency and minimized off-target effects
  • 5.5. Regulatory approvals of novel RNAi therapeutics fueling investment in rare genetic disorder applications
  • 5.6. Strategic partnerships between biopharma firms and academia to innovate RNAi delivery technologies
  • 5.7. Integration of CRISPR screening with RNAi libraries to accelerate target validation in neurodegenerative disease research
  • 5.8. Development of sustainable manufacturing processes for large-scale production of RNA interference constructs
  • 5.9. Exploration of inhalable RNAi formulations for localized pulmonary disease management and delivery
  • 5.10. Growing focus on precision delivery platforms for tissue-specific RNAi therapeutics in cardiovascular diseases

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNA Interference Technology Market, by Molecule Type

  • 8.1. MicroRNA (miRNA)
  • 8.2. Short Hairpin RNA (shRNA)
    • 8.2.1. Non-Viral Delivery shRNA
    • 8.2.2. Viral Delivery shRNA
  • 8.3. Small Interfering RNA (siRNA)
    • 8.3.1. Conjugated siRNA
    • 8.3.2. Non-Conjugated siRNA

9. RNA Interference Technology Market, by Route Of Administration

  • 9.1. Intramuscular (IM) Injection
  • 9.2. Intrathecal (IT) Administration
  • 9.3. Intravenous (IV) Injection

10. RNA Interference Technology Market, by Delivery Method

  • 10.1. Direct Naked RNAi Delivery
  • 10.2. Exosome-Based RNAi Therapy
  • 10.3. Nanoparticle-Based Delivery
  • 10.4. Viral Vector-Based Delivery

11. RNA Interference Technology Market, by Application

  • 11.1. Drug Discovery
    • 11.1.1. Lead Optimization
    • 11.1.2. Target Identification
  • 11.2. Research & Development
    • 11.2.1. Gene Function Studies
    • 11.2.2. Pathway Analysis
  • 11.3. Therapeutics

12. RNA Interference Technology Market, by End-User

  • 12.1. Contract Research Organizations
  • 12.2. Hospitals & Clinics
  • 12.3. Pharmaceutical & Biotechnology Companies

13. RNA Interference Technology Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. RNA Interference Technology Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. RNA Interference Technology Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Alnylam Pharmaceuticals, Inc.
    • 16.3.2. AMSBIO
    • 16.3.3. Arbutus Biopharma Corporation
    • 16.3.4. Arcturus Therapeutics Holdings Inc.
    • 16.3.5. Arrowhead Pharmaceuticals, Inc.
    • 16.3.6. Atalanta Therapeutics
    • 16.3.7. Bioneer Corporation
    • 16.3.8. Dicerna Pharmaceuticals, Inc.
    • 16.3.9. Gradalis, Inc.
    • 16.3.10. Horizon Therapeutics plc
    • 16.3.11. Ionis Pharmaceuticals, Inc.
    • 16.3.12. Merck KGaA
    • 16.3.13. Novartis AG
    • 16.3.14. Nutcracker Therapeutics, Inc.
    • 16.3.15. Phio Pharmaceuticals Corp.
    • 16.3.16. ProQR Therapeutics N.V.
    • 16.3.17. Sanofi S.A.
    • 16.3.18. Silence Therapeutics PLC
    • 16.3.19. Sirnaomics, Inc.
    • 16.3.20. Thermo Fisher Scientific Inc.
    • 16.3.21. Vir Biotechnology, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. RNA INTERFERENCE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. RNA INTERFERENCE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RNA INTERFERENCE TECHNOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MICRORNA (MIRNA), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MICRORNA (MIRNA), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MICRORNA (MIRNA), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MICRORNA (MIRNA), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MICRORNA (MIRNA), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-VIRAL DELIVERY SHRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-VIRAL DELIVERY SHRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-VIRAL DELIVERY SHRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-VIRAL DELIVERY SHRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-VIRAL DELIVERY SHRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-VIRAL DELIVERY SHRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL DELIVERY SHRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL DELIVERY SHRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL DELIVERY SHRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL DELIVERY SHRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL DELIVERY SHRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL DELIVERY SHRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONJUGATED SIRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONJUGATED SIRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONJUGATED SIRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONJUGATED SIRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONJUGATED SIRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONJUGATED SIRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-CONJUGATED SIRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-CONJUGATED SIRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-CONJUGATED SIRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-CONJUGATED SIRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-CONJUGATED SIRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NON-CONJUGATED SIRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAMUSCULAR (IM) INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAMUSCULAR (IM) INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAMUSCULAR (IM) INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAMUSCULAR (IM) INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAMUSCULAR (IM) INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAMUSCULAR (IM) INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRATHECAL (IT) ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRATHECAL (IT) ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRATHECAL (IT) ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRATHECAL (IT) ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRATHECAL (IT) ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRATHECAL (IT) ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAVENOUS (IV) INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAVENOUS (IV) INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAVENOUS (IV) INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAVENOUS (IV) INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAVENOUS (IV) INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY INTRAVENOUS (IV) INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DIRECT NAKED RNAI DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DIRECT NAKED RNAI DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DIRECT NAKED RNAI DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DIRECT NAKED RNAI DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DIRECT NAKED RNAI DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DIRECT NAKED RNAI DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY EXOSOME-BASED RNAI THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY EXOSOME-BASED RNAI THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY EXOSOME-BASED RNAI THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY EXOSOME-BASED RNAI THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY EXOSOME-BASED RNAI THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY EXOSOME-BASED RNAI THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NANOPARTICLE-BASED DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NANOPARTICLE-BASED DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NANOPARTICLE-BASED DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NANOPARTICLE-BASED DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NANOPARTICLE-BASED DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY NANOPARTICLE-BASED DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL VECTOR-BASED DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL VECTOR-BASED DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL VECTOR-BASED DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL VECTOR-BASED DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL VECTOR-BASED DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY VIRAL VECTOR-BASED DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GENE FUNCTION STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GENE FUNCTION STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GENE FUNCTION STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GENE FUNCTION STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GENE FUNCTION STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY GENE FUNCTION STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PATHWAY ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PATHWAY ANALYSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PATHWAY ANALYSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PATHWAY ANALYSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PATHWAY ANALYSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PATHWAY ANALYSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY MOLECULE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SHORT HAIRPIN RNA (SHRNA), 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY SMALL INTERFERING RNA (SIRNA), 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST RNA INTERFERENCE TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 284. MIDD